In addition, a clinical trial conducted on patients with CRPC determined that CDCA1 peptide vaccination could induce peptide-specific cytotoxic T lymphocytes in patients with CRPC.[18] CDCA2 is a nuclear protein that binds to protein phosphatase 1γ, which is responsible for the targeting of protein phosphatase 1 to chromatin during anaphase and controls cell proliferation in vitro.[19] Zhang et al[20] found that CDCA2 is overexpressed in PCa and many other cancer types, and that it acts as an oncogene in PCa, which has been demonstrated in in vivo and in vitro studies. This evidence concerns the gene NUF2 and cancer.